Shilpa Medicare Limited announced a strategic partnership with Swiss biotech firm NXI Therapeutics AG for the long-term development and commercial manufacturing of an NCE targeting autoimmune and alloimmune disorders. This mandate covers comprehensive CMC development, scale-up, and GMP supply. The collaboration enhances Shilpa’s role as a lifecycle partner and strengthens its CDMO platform, signaling robust growth visibility in high-value therapeutics.
Shilpa Medicare Forms Strategic Alliance with NXI Therapeutics
Shilpa Medicare Limited (SML) has entered into a significant, long-term strategic partnership with NXI Therapeutics AG, a Switzerland-based company, for the development and commercial manufacturing of a New Chemical Entity (NCE). This agreement, announced on February 14, 2026, reinforces SML’s accelerating biotech traction and enhances its long-term revenue visibility.
Scope of the Collaboration
Under the terms of the binding agreement, Shilpa group will provide comprehensive support across the product lifecycle, including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The initial focus is on an NCE intended to treat autoimmune and alloimmune disorders. The agreement is structured as a strategic collaboration, supporting development through first-in-human clinical studies.
NXI Therapeutics, a firm focused on next-generation safe immunotherapies, views Shilpa as an ideal partner due to its scientific depth, quality systems, and scalable GMP manufacturing capabilities.
Rationale and Benefits for Shilpa
The autoimmune and immune-modulation segment is recognized globally as one of the fastest-growing therapeutic areas. By securing this mandate at an early stage, Shilpa enhances its participation in high-value, innovation-driven pipelines.
Mr. Vishnukanth Bhutada, Managing Director of Shilpa Medicare, commented that this collaboration reinforces the company’s transformation into a strategic innovation partner for global biotech entities. The arrangement is expected to strengthen SML capability and know-how in the innovative side of therapies.
Key Details from Annexure-1
The agreement is classified as an International entity contract.
- Scope of Business: Development and supply of NCE, including commercial supply across territories.
- Related Party Status: NXI Therapeutics AG is not a related party to SML or its promoter group/companies.
- Expected Benefit: Ability to develop, manufacture, and supply the NCE critical for treating autoimmune conditions, while strengthening SML’s CDMO platform visibility.
The financial terms remain confidential, but the agreement includes milestone-linked expansion potential, possibly evolving into a multi-year commercial supply relationship contingent upon successful clinical and regulatory progression.
Source: BSE
